Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Leiomyosarcoma Clinical Trial

— TRASTS  

Official title:

Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02275286
• Other study ID #: GEIS 37
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 2014
• Est. completion date: June 2028

Study information

• Verified date: May 2023
• Source: Grupo Espanol de Investigacion en Sarcomas
• Contact: Adriana Rojo
• Phone: 0034912866807
• Email: adriana.crc[@]grupogeis.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in four cohorts of patients: Cohort A: Patients with diagnosis of non-operable or unresectable or not oncologically recommended metastasectomy of limited to lung metastases soft tissue sarcoma. Cohort B: Patients with locally advanced resectable Myxoid Liposarcoma. Cohort C: Patients with retroperitoneal and resectable soft tissue sarcoma (liposarcoma and leiomyosarcoma). Cohort D (Phase II only): Patients with well differentiated liposarcoma and G2 dedifferentiated liposarcoma (with less than 30% dedifferentiated component). Phase I: escalating dose of 1.3 or 1.5 mg/m2. Phase I for cohort C: de-escalating dose of 1.5 or 1.3mg/m2 Radiotherapy for cohort A: 30Gy in 10 fractions (3Gy/fraction). Radiotherapy for cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Radiotherapy for cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Radiotherapy for cohort D: 45Gy in 25 fractions (1.8Gy/fraction). A translational substudy is developed to analyse different biomarkers predictive value. Cohorts A and B are closed to recruitment in 2023.

Description:

In this study investigators plan to measure tumor response (RECIST and Choi criteria) when administering trabectedin standard dose or inferior with simultaneous radiotherapy treatment. The hypothesis states that administering trabectedin at 1.3mg/m2 or ≤1.5mg/m2 plus Radiotherapy 30-45Gy shows synergic activity that turns into tumor shrinkage. A phase I trial (dose escalation -or de-escalation for cohort C- level of 1.3 or 1.5 mg/m2) will provide the proper dose level to perform a phase II trial to measure RECIST and Choi response, progression free survival, overall survival and register safety and quality of life details. Four cohorts are indicated for this trial: Cohort A: Patients with diagnosis of non-operable or unresectable or not oncologically recommended metastasectomy of limited to lung metastases soft tissue sarcoma. Cohort B: Patients with locally advanced resectable Myxoid Liposarcoma, Cohort C:Patients with retroperitoneal and resectable soft tissue sarcoma (liposarcoma and leiomyosarcoma). Cohort D: Patients with well differentiated liposarcoma and G2 dedifferentiated liposarcoma (with less than 30% dedifferentiated component) Unlimited cycles of chemotherapy are considered to be beneficial for cohort A patients, whereas cohort B and C only 3 cycles are indicated. About radiotherapy treatment, 30Gy will be given to cohort A patients, whereas cohort B and C will receive 45Gy. TCs and MRI are selected for imaging purposes. Phase I: For cohorts A and B:Trabectedin at two dose escalation levels: 0 1.3 mg/m2 as a 24h I.V. infusion 1 1.5 mg/m2 as a 24h I.V. infusion For cohort C:Trabectedin at two dose de-escalation levels: 0 1.5 mg/m2 as a 24h I.V. infusion -1 1.3 mg/m2 as a 24h I.V. infusion Administration of trabectedin with a portable pump, i.v infusion of 24h, in cycles of 3 weeks. Premedication: - 4 mg oral dexamethasone 24h and 12h before chemotherapy administration. - 20 mg I.V. dexamethasone 30minutes before treatment. - Ondansetron or analogue will also be given prior to trabectedin. Pathology review, radiology review and radiotherapy review are performed to each patient. Several biomarkers are selected to perform FFPE tumor assays in relation to prediction

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 199
• Est. completion date: June 2028
• Est. primary completion date: June 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Cohort A: STS

Inclusion Criteria:

1. The patient must sign voluntarily the informed consent form before any study test is conducted that is not part of routine patient care.

2. Aged equal or over 18.

3. Patients must have a diagnostic of Soft Tissue Sarcoma with metastasis limited to lung, and not suitable for metastasectomy or surgery resection or not oncologically recommended metastasectomy.A centralized diagnostic will be performed, the tumor sample must be available and sent prior to inclusion.

4. Disease distribution allows meeting with normal tissue constraints of radiation therapy. Radiation oncologist must confirm this point.

5. Metastatic spread could be present in two organs at maximum (i.e. lungs and pelvic fosa).

6. Those lesions considered for radiation therapy have to be considered as target lesions as well. (i.e. in a patient with nodules in lungs, those lesions selected for radiation therapy have to include at least the target lesions)

7. It is allowed that not all the lesions will be under radiation fields. As a general rule, it will be prioritized to select, as target-irradiating lesions, those with greater increase in size and those largest lesions. It should be discouraged to irradiate pulmonary lesions with infiltration of pleural serosa.

8. Patients must have documentation of disease progression within 6 months prior to study entry.

9. The patient must have been considered eligible for systemic chemotherapy. A maximum of two previous lines for advanced/metastatic disease are allowed as long as trabectedin has not been included.

10. The following histological subtypes can be included:

Undifferentiated pleomorphic sarcoma (previously, malignant fibrous histiocytoma) Leiomyosarcoma Angiosarcoma/ epithelial hemangioendothelioma Liposarcoma and its variants (well differentiated, dedifferentiated, myxoid/round cells, pleomorphic). Synovial sarcoma Fibrosarcoma and its variants (epithelial fibrosarcoma/low grade fibromyxoid sarcoma) Hemangiopericytoma/solitary fibroid tumor Neurogenic sarcoma (Malignant peripheral nerve sheath tumor, MPNST) Myxofibrosarcoma Epithelioid Sarcoma Unclassified sarcoma (spindle cell/epithelioid/pleomorphic/myxoid)

11. Measurable disease, according to RECIST V 1.1 criteria

12. Performance status =1 (ECOG).

13. Adequate respiratory functions: FEV1 >1L; DLco > 40% (patients with pulmonary target lesions)

14. Adequate bone marrow function (hemoglobin > 10 g/dl, leukocytes = 3.000/mm3, neutrophils = 1.500/mm3, platelets = 100.000/mm3). Patients with plasma creatinine = 1,6 mg/dl, transaminases = 2.5 times the UNL, total bilirubin = UNL, CPK = 2.5 times UNL, alkaline phosphatase = 2.5 times the UNL are acceptable. If the increase of alkaline phosphatase is > 2.5 times the UNL, then the alkaline phosphatase liver fraction and/or GGT must be = UNL.

15. Men or women of child bearing potential should be using an effective method of contraception before entry into the study and throughout the same and for 6 months after ending the study. Women of childbearing potential must have a negative urine pregnancy test before study entry.

16. Normal cardiac function with a LVEF = 50% by echocardiogram or MUGA.

17. It should be performed HBV and HCV serologies prior to inclusion. If HbsAg is positive it is recommended to reject the existence of replicative phase (HbaAg+, DNA VHB+). If these were positives the inclusion is not recommended, remaining at investigators' discretion the preventive treatment with lamivudine. If a potential patient is positive for anti-HCV antibodies, presence of the virus should be ruled out with a qualitative PCR, or the patient should NOT be included in the study (if a qualitative PCR cannot be performed then patient will not be able to enter the study)

18. Patient must have a Central Venous Catheter for treatment

Exclusion Criteria:

1. Previous treatment with trabectedin or previous treatment with radiotherapy (except if previous radiotherapy treatment plus planned study radiotherapy treatment allow tissues constrains)

2. Performance status = 2 (ECOG).

3. Plasma bilirubin > UNL.

4. Creatinine > 1.6 mg/dL.

5. History of other neoplastic disease with less than 5 years free of disease with the exception of basal cell carcinoma or in situ cervical cancer adequately treated.

6. Severe COPD or other severe pulmonary diseases.

7. Significant cardiovascular disease (for example, dyspnea > 2 NYHA)

8. Significant systemic diseases grade 3 or higher on the NCI-CTCAE v4.03 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity.

9. Uncontrolled bacterial, mycotic or viral infections.

10. Known positive test for infection by human immunodeficiency virus (HIV).

11. Women who are pregnant or breast-feeding.

12. Psychological, familial, social or geographic circumstances that limit the patient"s ability to comply with the protocol or informed consent.

13. Patients participating in another clinical trial or receiving any other investigational product

14. Patients who had participated in another clinical trial and/or had received any other investigational product in the last 30 days prior to inclusion.

15. Histologies other than those described in inclusion criteria. Cohort B: ML

Inclusion criteria:

1. The patient must sign voluntarily the informed consent form before any study test is conducted that is not part of routine patient care.

2. Age =18 years old.

3. Pathological diagnosis of Myxoid Liposarcoma, deep located and more than 5 cm or superficial more than 10 cm. A centralized diagnostic will be performed to confirm that the patient can be included in the study.

4. Tumor must be resectable and without evidence of regional or distal spread after adequate staging procedure. Tumor must be located in limbs or superficial trunk wall.

5. Disease distribution allows meeting with normal tissue constraints of radiation therapy. Radiation oncologist must confirm this point.

6. Measurable disease, according to RECIST V 1.1 criteria

7. Performance status 0-1 (ECOG).

8. Adequate bone marrow function (hemoglobin > 10 g/dL, leukocytes = 3.000/mm3, neutrophils = 1.500/mm3, platelets = 100.000/mm3). Patients with plasma creatinine = 1,6 mg/dL, transaminases = 2.5 times the UNL, total bilirubin = UNL, CPK = 2.5 times UNL, alkaline phosphatase = 2.5 times the UNL are acceptable. If the increase of alkaline phosphatase is > 2.5 times the UNL, then the alkaline phosphatase liver fraction and/or GGT must be = UNL.

9. Men or women of child bearing potential should be using an effective method of contraception before entry into the study and throughout the same and for 6 months after ending the study. Women of childbearing potential must have a negative urine pregnancy test before study entry.

10. Normal cardiac function with a LVEF = 50% by echocardiogram or MUGA.

11. It should be performed HBV and HCV serologies prior to inclusion. If HbsAg is positive it is recommended to reject the existence of replicative phase (HbaAg+, DNA HBV+). If these were positives the inclusion is not recommended, remaining at investigators' discretion the preventive treatment with lamivudine. If a potential patient is positive for anti-HCV antibodies, presence of the virus should be ruled out with a qualitative PCR, or the patient should NOT be included in the study (if a qualitative PCR cannot be performed then patient will not be able to enter the study).

12. Patient may have had one previous chemotherapy line.

13. Patient must have a Central Venous Catheter for treatment.

Exclusion criteria:

1. Unresectable tumors (with limb sparing surgery)

2. More than one previous chemotherapy treatment for local disease including trabectedin.

3. Radiotherapy involving the tumoral bed.

4. Performance status = 2 (ECOG).

5. Presence of metastases or lymph node involvement by the tumor.

6. Location other than limb or superficial trunk wall.

7. Plasma bilirubin > UNL.

8. Creatinine > 1.6 mg/dL.

9. History of other neoplastic disease with less than 5 years free of disease with the exception of basal cell carcinoma or in situ cervical cancer adequately treated.

10. Significant cardiovascular disease (for example, dyspnea > 2 NYHA)

11. Significant systemic diseases grade 3 or higher on the NCI-CTCAE v4.03 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity.

12. Uncontrolled bacterial, mycotic or viral infections.

13. Known positive test for infection by human immunodeficiency virus (HIV).

14. Women who are pregnant or breast-feeding.

15. Psychological, familial, social or geographic circumstances that limit the patient"s ability to comply with the protocol or informed consent.

16. Patients who had participated in another clinical trial and/or had received any other investigational product in the last 30 days prior to inclusion. Cohorts C and D: Retroperitoneum sarcoma

Inclusion criteria:

1. The patient must voluntarily sign the informed consent form before performing any study-specific test that is not part of the patient's usual care.

2. Aged between 18 and 75 years.

3. The following histological subtypes may be included in the cohort C:

High grade leiomyosarcoma (G2-3), liposarcoma (G2-3), if at least 30% of the tumour is dedifferentiated, pleomorphic liposarcoma. The following histological subtypes may be included in the cohort D: Well differentiated liposarcoma (WD liposarcoma) and G2 dedifferentiated liposarcorcoma, if less than 30% of the tumour is dedifferentiated. A centralised diagnosis will be made to confirm that the patient can be included in the study.

4. The tumour must be located in the retroperitoneum and it must be resectable and without evidence of regional or distal spread after the appropriate staging process. This point must be confirmed by the central surgeon reviewer.

5. The location and size of the disease in the retroperitoneum must allow for compliance with radiotherapy limitations in healthy tissue. This point must be confirmed by the site's radiation oncologist and the central radiation oncologist reviewer.

6. Measurable disease according to CHOI criteria for cohort C and RECIST V 1.1 criteria for cohort D.

7. ECOG performance status 0-1.

8. Adequate haematological parameters (haemoglobin >10 g/dl, leukocytes =3,000/mm3, neutrophils =1,500/mm3, platelets =100,000/mm3). Patients with plasma creatinine =1.6 mg/dl, transaminases =2.5 times the ULN, total bilirubin = ULN, CPK =2.5 times ULN, alkaline phosphatase =2.5 times ULN are acceptable. If the increase in alkaline phosphatase is >2.5 times the ULN, the liver fraction of alkaline phosphatase and/or GGT should be =ULN.

9. Fertile men or women must use an effective contraceptive method before starting the study, during the study and for 6 months following the conclusion thereof. Women of childbearing potential who participate in the study must undergo a pregnancy test before starting the study.

10. Normal cardiac function with LVEF =50% by echocardiogram or MUGA.

11. HBV and HCV serology must be performed before including the patient in the study. If HbsAg is positive, it is advisable to rule out a replicative phase (HbsAg*, DNA HBV+). If positive, the patient's inclusion in the trial is not recommended, and it is at the discretion of the investigator to administer preventive treatment with lamivudine. If a potential patient is positive to anti-HCV antibodies, the presence of the virus will be ruled out with a qualitative PCR, or the patient cannot be included in the study (if the qualitative PCR test cannot be performed on the patient, they cannot be included in the study).

12. Patient may have had one previous chemotherapy line (cohort D only).

13. The patient must have a central venous catheter for the administration of the treatment. Exclusion criteria

1. Unresectable tumours.

2. Location other than the retroperitoneum.

3. Patients who have previously received systemic treatment with chemotherapy (trabectedin included). For cohort D, patients may have received one previous line of chemotherapy with any other agent.

4. Patients who underwent prior local treatment for retroperitoneal sarcoma: surgery or radiotherapy in the tumour bed.

5. ECOG performance status =2.

6. Presence of metastasis or lymph node involvement of the tumour.

7. Previous history of another neoplastic disease with less than 5 years free of disease except for basal cell carcinoma or properly treated in situ cervical cancer.

8. Significant cardiovascular disease (e.g. dyspnoea >2 NYHA).

9. A significant grade 3 or greater systemic disease on the NCI-CTCAE v4.03 scale, which may limit the availability of the patient or which, in the opinion of the investigator, may contribute to the toxicity caused by the study treatment.

10. Uncontrolled viral, mycotic or bacterial infections.

11. Known HIV-positive patients.

12. Pregnant or breast-feeding women.

13. Psychological, familial, social or geographical circumstances that limit the patient's ability to comply with the protocol or informed consent form.

14. Patients who have participated in another clinical trial and/or have received another investigational product in the 30 days prior to inclusion in the trial.

Related Conditions & MeSH terms

• Leiomyosarcoma
• Liposarcoma
• Liposarcoma, Myxoid
• Pleomorphic Liposarcoma
• Sarcoma
• Sarcoma, Soft Tissue

Intervention

Drug:
• Trabectedin
Escalating or deescalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks. Cohort A: unlimited cycles. Cohort B: 3 cycles. Cohort C: 3 cycles. Cohort D: cycles of trabectedin will be provided and patients will subsequently be evaluated for surgery.

Radiation:
• Radiotherapy
3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction). Cohort B: 45Gy in 25 fractions (1.8Gy/fraction). Cohort C: 45Gy in 25 fractions (1.8Gy/fraction). Cohort D: 45Gy in 25 fractions (1.8Gy/fraction).

Locations

Country	Name	City	State
France	Institut Bergonié	Bordeaux
France	Centre Léon Berard	Lyon
Italy	Centro di Referimento Ocologico	Aviano
Italy	Istituto Ortopedico Rizzoli	Bologna
Italy	Candiolo Cancer Institute	Candiolo
Italy	Istituto Nazionale dei Tumori	Milan
Italy	Istituto Clinico Humanitas	Rozzano	Milan
Spain	Hospital Sant Pau	Barcelona	Cataluña
Spain	Hospital Vall d'Hebrón	Barcelona
Spain	Hospital Puerta de Hierro	Madrid
Spain	Hospital Uniersitario La Paz	Madrid
Spain	Hospital Universitario Gregorio Marañón	Madrid
Spain	Jiménez Díaz Foundation University Hospital	Madrid
Spain	Hospital Son Espases	Palma de Mallorca	Mallorca
Spain	Hospital Universitario Canarias	San Cristobal de la Laguna	Tenerife
Spain	Hospital Virgen del Rocío	Sevilla
Spain	Hospital Miguel Servet	Zaragoza	Aragón

Sponsors (3)

Lead Sponsor	Collaborator
Grupo Espanol de Investigacion en Sarcomas	Centre Leon Berard, Italian Sarcoma Group

Countries where clinical trial is conducted

France,  Italy,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor size	Image tumor assessment: RECIST response for the combination of trabectedin plus radiation therapy in cohorts A and B. CHOI response for the combination of trabectedin plus radiation therapy in cohort C.	every 6 weeks for 24 months
Primary	Relapse-free survival.	In cohort D to improve 5-year relapse-free survival (RFS), decreasing the 5-year relapse percentage from 30% to 10% in patients with well differentiated liposarcoma with cellular component and dedifferentiated G2 retroperitoneal resected liposarcoma (20% increase in RFS).	5 years.
Secondary	Number and grade of adverse events	CTCAE v4.03 adverse events registration to evaluate safety	every 21 days until 30 days after last dose or during 25 months
Secondary	Number of months without progression	Progression free survival (PFS)	24 months
Secondary	Number of months alive	Overall survival (OS)	24 months
Secondary	Tumor size	Image tumor assessment measured by Choi criteria.	every 6 weeks during 24 months (cohort A) or every 4months during 36 months (cohort B and C)
Secondary	Questionnaire	QLQ-C30 EORTC questionnaire to evaluate patient quality of life	every 3 months during 24 months
Secondary	Overall response rate (ORR)	Sum of complete responses, partial responses and stable diseases	every 6 weeks during 24 months
Secondary	relapse free survival (RFS) at 3 years (cohorts C and D)	percentage of relapses from diagnosis at 3 years	After 3 year since last patient treatment initiation
Secondary	relapse at 5 years (cohorts C and D)	number of months without relapse from treatment initiation until 5 years.	After 5 years since last patient treatment initiation
Secondary	Tumor cells response to the treatment	Number of tumor necrotic cells	Week 11, at surgery
Secondary	Predictive and prognostic biomarker	percentage of protein and RNA expression of FAS, Ca2+ and NER pathways in tumor samples obtained at baseline and at surgery (approx week 11)	Baseline and week 11 (at surgery)